Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history

Kenji Ota1, Satoshi Murakami2, Kaori Ishihara1

  • 1Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Vaccine: X
|March 24, 2023
PubMed

The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.